期刊文献+

血清SCCA水平及盆腔淋巴结HPV 16/18感染状况与宫颈鳞癌患者预后的关系 被引量:7

The relation of serum squamous cell carcinoma antigen level and pelvic lymph node HPV 16/18 infection with prognosis of cervical squamous cell carcinoma
下载PDF
导出
摘要 目的探讨术前血清SCCA水平、盆腔淋巴结HPV 16/18感染状况与宫颈鳞癌患者预后的关系。方法ELISA法检测血清SCCA水平,实时荧光定量PCR法检测盆腔淋巴结HPV 16/18感染,分析二者与宫颈鳞癌患者3年生存率的关系。结果血清SCCA水平与盆腔淋巴结HPV 16/18感染相关(P<0.05)。35例宫颈鳞癌患者中位随访36个月(12~41月),死亡4例,3年总体生存率为85.0%。血清SCCA阴性者和阳性者的3年生存率分别为100%和69.2%;盆腔淋巴结HPV 16/18阴性者和阳性者的3年生存率分别为96.4%和57.1%;血清SCCA及盆腔淋巴结HPV 16/18阴性患者的3年生存率明显优于阳性者(P<0.05)。淋巴结转移、血清SCCA和淋巴结HPV16/18与宫颈鳞癌患者的预后相关。结论血清SCCA水平及盆腔淋巴结HPV 16/18感染状况与宫颈鳞癌患者预后相关,可作为宫颈鳞癌预后判断指标。 Objective To explore the relation of preoperative serum SCCA levels,pelvic lymph node HPV 16/18 infection in patients with cervical squamous cell carcinoma and their prognosis.Methods ELISA was performed to detect the SCCA level and real-time fluorescence quantitative PCR was utilized to analyze the positive rate of pelvic lymph node infection with HPV 16/18.The relation of SCCA level,HPV 16/18 positive rate and the three-year survival rate was investigated.Results The SCCA level was closely related with the infection of HPV 16/18 in pelvic lymph node(P0.05).The mean follow-up time for 35 patients with cervical squamous cell carcinoma was 36 m(rang 12~41 months).Four patients died and 3 year survival rate was 85.0%.The 3 year survival rates for patients with SCCA positive and negative were 100% and 69.2% respectively and that were 96.4% and 57.1% for patients with positive or negative pelvic lymph node infection with HPV 16/18.The 3-year survival rate for patients with negative SCCA and lymph node HPV 16/18 infection were obviously longer than that of positive ones(P0.05).lymph node metastasis,SCCA level and pelvic lymph node HPV 16/18 infection status were associated with prognosis.Conclusions SCCA level and pelvic lymph node HPV 16/18 infection are associated with the prognosis of cervical squamous carcinoma patients and is a potential markers for cervical squamous carcinoma.
出处 《基础医学与临床》 CSCD 北大核心 2012年第10期1167-1170,共4页 Basic and Clinical Medicine
基金 江西省卫生厅基金(20081122)
关键词 宫颈肿瘤 鳞状细胞癌抗原 人乳头瘤病毒 预后 cervical neoplasms squamous cell carcinoma antigen human papillomavirus prognosis
  • 相关文献

参考文献8

  • 1丁洪慧,曾四元,熊辉,刘晖.宫颈癌患者淋巴结HPV16/18感染及血清鳞状细胞癌抗原检测的临床意义[J].现代妇产科进展,2010,19(7):523-526. 被引量:4
  • 2高宝荣,赵桂玲,张虹.SCC-Ag对早期宫颈癌患者淋巴结转移评估的价值[J].中国肿瘤临床,2010,37(11):630-633. 被引量:26
  • 3Olsen JR, Dehdashti F, Siegel BA, et al. Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cer- vix: association with pre- and posttreatment FDG-PET[ J]. Int J Radiat Oncol Biol Phys, 2011,81:772 -777.
  • 4孙颖,刘国炳,余艳红.盆腔淋巴结HPV-DNA检出率与早期宫颈癌临床转移的关系[J].中华肿瘤防治杂志,2011,18:1259-1261.
  • 5Gadducci A, Tana R, Cosio S, et al. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a re- view of the literature [ J ]. Crit Rev Oncol Hematol, 2008, 66:10 -20.
  • 6Noordhuis MG, Eijsink JJ, Roossink F, et al. Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo) radiation : a systematic review [ J ]. Int J Radiat Oncol Biol Pbys,2011,79:325 - 34.
  • 7Li N, Franceschi S, Howell-Jones R, et al. Human papillo- mavirus type distribution in 30,848 invasive cervical canc- ers worldwide: Variation by geographical region, histologi- cal type and year of publication [ J ]. Int J Cancer, 2011, 128:927 - 935.
  • 8骆成玉,祝学光.肿瘤微转移检测研究的现状和存在的问题[J].基础医学与临床,2004,24(5):578-581. 被引量:4

二级参考文献40

  • 1冯淑瑜,张彦娜,刘建刚.宫颈癌淋巴结转移的高危因素及预后分析[J].癌症,2005,24(10):1261-1266. 被引量:71
  • 2荆结线,邵淑丽,田保国,韩存芝,赵先文,杜丽丽,张中书.宫颈癌SCCAg检测及其临床意义[J].中国肿瘤临床,2005,32(21):1242-1244. 被引量:13
  • 3熊樱,梁立治,郑敏,魏梅,沈扬.鳞状细胞癌抗原与子宫颈鳞状细胞癌的临床病理特征及预后的关系[J].中华妇产科杂志,2007,42(1):29-33. 被引量:36
  • 4Murakami A,Nakagawa T,Fukushima C,et al.Relationship between decreased expression of squamous cell carcinoma antigen 2 and E-cadherin in primary cervical cancer lesions and lymph node metastasis[J].Oncol Rep,2008,19(1):99-104.
  • 5Kim YT,Yoon BS,Kim JW,et al.Pretreatment levels of serum squamous cell carcinoma antigen and urine polyamines in women with squamous cell carcinoma of the cervix[J].Int J Gynaecol Obstet,2005,91(1):47-52.
  • 6Brioschi PA,Bischof P,Delafosse C,et al.Squamous-cell carcinoma antigen (SCO-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma[J].Int J Cancer,1991,47(3):376-379.
  • 7Aoki Y,Sasaki M,Watanabe M,et al.High-risk group in node-positive patients with stage IB,IIA,and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation[J].Gynecol Oncol,2000,77(2):305-309.
  • 8Sakuragi N,Satoh C,Takeda N,et al.Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB,IIA,and IIB cervical carcinoma treated with radical hysterectomy[J].Cancer,1999,85(7):1547-1554.
  • 9Duk JM,Groenier KH,de Bruijn HW,et al.Pretreatment serum squamous cell carcinoma antigen:a newly identified prognostic factor in early-stage cervical carcinoma[J].J Clin Oncol,1996,14(1):111-118.
  • 10Avail-Lundqvist EH,Sjovall K,Nilsson BR,et al.Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma[J].Eur J Cancer,1992,28A(10):1695-1702.

共引文献32

同被引文献87

引证文献7

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部